Lundbeck was founded by Hans Lundbeck as a trading company in 1915. In its early years, Lundbeck was solely a trading company, supplying Danish people with everything from synthetic sugar to silver paper. The recruitment of Eduard Goldschmidt in 1924 marked the beginning of Lundbeck’s ascent into the pharmaceutical industry, bringing several agencies for medicines into the company.
Today, Lundbeck is a specialized pharmaceutical company focusing on psychiatry and neurology. For more than 70 years, we have been at the forefront of research within neuroscience. Our development and distribution of pioneering treatments continues to make a difference to people living with psychiatric and neurological disorders. Every day we strive for better treatments and improved quality of life for people living with psychiatric and neurological disorders.
Lundbeck is engaged in the entire value chain from research, development and production to marketing and sale of pharmaceuticals across the world. The company’s products are targeted at psychiatric and neurological disorders such as depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.
Lundbeck employs approximately 5,000 people worldwide. Lundbeck employs approximately 800 highly-trained specialists and our research facilities are located in Valby, Denmark.
Lundbeck’s production facilities are located in Denmark, France and Italy.
Lundbeck has affiliates in more than 50 countries, primarily focusing on sales, and our products are registered in more than 100 countries. In 2017, Lundbeck continued to make positive progress in International Markets and North America and we generated revenue of DKK 17.2 billion.
If you are interested in more specific information about one of our affiliates, please visit their local websites.